CXCR4 and hematologic disorder: Since CIML NK cells are being used for the treatment of hematological malignancies (clinical trials NCT01898793, NCT03068819, and NCT02782546), it would be preferable that they express higher levels of CXCR4 in order to improve the trafficking to the bone marrow.